San Diego — Auxilium Biotechnologies has officially launched a pivotal clinical trial to evaluate the safety and effectiveness of its investigational medical device, NeuroSpan Bridge™, which is designed to aid in nerve regeneration and restore function for patients with peripheral nerve injuries. The first patient has been enrolled in the trial, marking a major milestone for the company’s regenerative medicine platform.
The trial, named Neurospan-1, aims to recruit 80 participants at sites across the United States. It will test whether the NeuroSpan Bridge can outperform existing treatments by improving motor and sensory recovery while minimizing complications such as chronic pain—one of the more frequent issues associated with conventional nerve repair procedures.
The NeuroSpan Bridge is a bioengineered device that mimics the fascicular architecture of nerves using microchannels. These microstructures are designed to guide regenerating axons along the correct pathways as they cross an injury site, organizing the regeneration process and helping to restore natural function more precisely.
“We’ve spent years developing a technology with the potential to change lives, and today, we are one step closer to making that a reality,” said Dr. Jacob Koffler, CEO of Auxilium Biotechnologies. “This trial represents an important moment for the field of nerve repair and for the patients who may one day benefit from our innovation.”
Auxilium’s approach combines advances in regenerative science, biomaterials engineering, and medical device technology. The company is known for its bold scientific vision, including past work in microgravity bioprinting aboard the International Space Station, where implantable devices were successfully fabricated in zero gravity conditions.
The launch of the Neurospan-1 trial underscores Auxilium’s long-term mission to restore lost nerve function, especially for patients whose injuries stem from traumatic events like car accidents or workplace incidents. If successful, NeuroSpan Bridge could provide a transformative new option for individuals suffering from life-altering nerve damage.
With enrollment now underway, Auxilium is moving steadily toward its goal of setting a new standard in nerve regeneration therapy and improving outcomes for patients facing the physical and emotional toll of severe nerve injuries.
